CLINICAL_TRIALS
trial_result
· 2021-01-29
Clinical Trial Update: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer [Phase 2]
Summary
Phase 2 trial investigating circulating tumor DNA-guided olaparib (Lynparza) treatment in ovarian epithelial cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Ovarian Epithelial Cancer | Phase 2 | Status: UNKNOWN